Next Article in Journal / Special Issue
Small Molecules Present in the Cerebrospinal Fluid Metabolome Influence Superoxide Dismutase 1 Aggregation
Previous Article in Journal
Adverse Impact of Diet-Induced Hypercholesterolemia on Cardiovascular Tissue Homeostasis in a Rabbit Model: Time-Dependent Changes in Cardiac Parameters
Previous Article in Special Issue
The Role of Initial Oligomers in Amyloid Fibril Formation by Human Stefin B
Int. J. Mol. Sci. 2013, 14(9), 19109-19127; doi:10.3390/ijms140919109

Single-Chain Fragment Variable Passive Immunotherapies for Neurodegenerative Diseases

Received: 7 August 2013 / Revised: 29 August 2013 / Accepted: 30 August 2013 / Published: 17 September 2013
(This article belongs to the Special Issue Protein Folding 2015)
View Full-Text   |   Download PDF [1061 KB, uploaded 19 June 2014]   |   Browse Figures


Accumulation of misfolded proteins has been implicated in a variety of neurodegenerative diseases including prion diseases, Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD). In the past decade, single-chain fragment variable (scFv) -based immunotherapies have been developed to target abnormal proteins or various forms of protein aggregates including Aβ, SNCA, Htt, and PrP proteins. The scFvs are produced by fusing the variable regions of the antibody heavy and light chains, creating a much smaller protein with unaltered specificity. Because of its small size and relative ease of production, scFvs are promising diagnostic and therapeutic reagents for protein misfolded diseases. Studies have demonstrated the efficacy and safety of scFvs in preventing amyloid protein aggregation in preclinical models. Herein, we discuss recent developments of these immunotherapeutics. We review efforts of our group and others using scFv in neurodegenerative disease models. We illustrate the advantages of scFvs, including engineering to enhance misfolded conformer specificity and subcellular targeting to optimize therapeutic action.
Keywords: scFv; immunotherapy; Prion disease; Alzheimer’s disease; Parkinson’s disease; Huntington’s disease; PrP; Aβ; SNCA; Htt scFv; immunotherapy; Prion disease; Alzheimer’s disease; Parkinson’s disease; Huntington’s disease; PrP; ; SNCA; Htt
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Huang, L.; Su, X.; Federoff, H.J. Single-Chain Fragment Variable Passive Immunotherapies for Neurodegenerative Diseases. Int. J. Mol. Sci. 2013, 14, 19109-19127.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert